

REFERENCES

- Abraham SN, St John AL. **Mast cell-orchestrated immunity to pathogens.** *Nat Rev Immunol.* 2010;10(6):440-52.
- Adiletta S, Candiello A, Arminio D, Porcaro S, Saporito G, Palomba R. **Sinergismo tra pregabalin e palmitoiletanolamide (PEA) nel trattamento della neuropatia diabetica.** 34° Congresso nazionale AISD Riccione 29-31 maggio 2011
- Aloe L, Leon A, Levi-Montalcini R. **A proposed autacoid mechanism controlling mastocyte behaviour.** *Agents Actions.* 1993;39 Spec No:C145-7.
- Anand P, Singh B, Jaggi AS, Singh N. **Mast cells: an expanding pathophysiological role from allergy to other disorders** Naunyn Schmiedebergs Arch Pharmacol. 2012;385(7):657-70.
- Assini A., Laricchia D., Belletti M., Pandolfini L., Pizzo R., Ratto S. **The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide.** 2010 EFNS European Journal of Neurology 17 (Suppl. 3)
- Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. **Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.** *CNS Neurol Disord Drug Targets.* 2013;12(1):34-44.
- Biasiotta A, Di Stefano G, Leone C, La Cesa S, Truini A, Crucco G. **Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clinical and neurophysiological open study. Preliminary results.** *NeuPSIG 2010 - 3rd International Congress on Neuropathic Pain.* 2010, Athens (Grecia)
- Bulanova E, Bulfone-Paus S. **P2 receptor-mediated signaling in mast cell biology** *Purinergic Signal.* 2010;6(1):3-17.
- Calabrò RS, Bramanti P. **Occipital Neuralgia Responding to Palmitoylethanolamide** *Headache.* 2013;.
- Canteri L, Petrosino S, Guida G. **Reducción del consumo de antiinflamatorios y analgésicos en el tratamiento del dolor neuropático crónico en pacientes afectados por lumbociatalgia de tipo compresivo y en tratamiento con normast® 300 mg.** *Dolor* 2010; 25(4):227-34
- Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. **Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.** *Vet Immunol Immunopathol.* 2010;133(1):9-15.
- Conigliaro R, Drago V, Foster PS., Schievano C, Di Marzo V. **Use of the Palmitoylethanolamide in the Entrapment Neuropathy of the Median in the Wrist.** *Minerva Medica.* 2011; 102(2):141-7.
- Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. **Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.** *Br J Pharmacol.* 2002 ;135(1):181-7.
- Costa B, Colombo A, Bettoni I, Bresciani E, Torsello A, Comelli F. **The endogenous lipid palmitoylethanolamide relieves neuropathic pain via mast cell and microglia modulation.** The 21st Annual Symposium of the International Cannabinoid Research Society. Jul. 06, 2011 - Jul 09, 2011 Chicago.
- Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. **The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.** *Pain.* 2008;139(3):541-50.
- Costa B, Conti S, Giagnoni G, Colleoni M. **Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems.** *Br J Pharmacol.* 2002 Oct;137(4):413-20.
- Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO. **Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis.** *PLoS One.* 2013;8(3):e60529.
- Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M. **Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism.** *Mediators of Inflammation* Volume 2013; 2013:328797.
- Dominguez CM, Martín A, Ferrer FG, Puertas MAI, Muro AL, González JCM, Prieto JP, Taberna IR. **N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica** *Pain Manage.* (2012) 2(2), 119–124
- Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. **Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.** *Brain Behav Immun.* 2011 Aug;25(6):1099-112.
- Forsythe P, Bienenstock J. **The mast cell-nerve functional unit: a key component of physiologic and pathophysiologic responses.** *Chem Immunol Allergy.* 2012;98:196-221.
- Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. **Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogeneses.** *Pain Med.* 2012; 13(9):1121-30.
- Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerde B. **Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity.** *Pain.* 2013, [in press].
- Gianfelice V, Lazzari M, Finocchi S, Frasca MG, Palombo E, Bellucci O, Luciani S, Guantero D, Divizia M, Gatti A. **Palmitoiletanolamide nel trattamento del dolore cronico associato a differenti eziopatogenesi** 36° Congresso Nazionale Associazione Italiana Associazione Italiana Verona, 30 maggio-1° giugno 2013
- Granberg M, Fowler CJ, Jacobsson SO. **Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leukaemic cells.** *Naunyn Schmiedebergs Arch Pharmacol.* 2001 ;364(1):66-73.
- Guida G, de Fabiani A, Lanaia F, Alexandre A, Vassallo GM, Cantieri L, de Martino M, Rogai M, Petrosino S. **La palmitoiletanolamida (normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico.** *Dolor.* 2010; 25:35-42
- Jack DB. **Alliamides: a new approach to the treatment of inflammation.** *DN&P;* 1996; 9(2):93-98
- Kim DY, Hong GU, Ro JY. **Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L.** *J Neuroinflammation.* 2011;8:25.
- Kim DY, Jeoung D, Ro JY. **Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis.** *J Immunol.* 2010;185(1):273-83.
- Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. **Nerve growth factor: from neurotrophin to neurokine.** *Trends Neurosci.* 1996;19(11):514-20.
- Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. **Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome.** *Anesthesiology.* 2012 Apr;116(4):882-95.
- Lundequist A, Pejler G. **Biological implications of preformed mast cell mediators.** *Cell Mol Life Sci.* 2011;68(6):965-75.
- Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S. **Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice.** *CNS Neurol Disord Drug Targets.* 2013;
- Luongo L, Palazzo E, de Novellis V, Maione S. **Role of Endocannabinoids in Neuron-Glial Crosstalk.** *The Open Pain Journal,* 2010, 3, 29-36.
- Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. **Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.** *J Orofac Pain.* 2012 Spring;26(2):99-104.
- Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. **N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.** *Eur J Pharmacol.* 1996;300(3):227-36.
- Medic N, Lorenz P, Vita F, Trevisan E, Marchioli A, Soranzo MR, Fabbretti E, Zabucchi G. **Mast cell adhesion induces cytoskeletal modifications and programmed cell death in oligodendrocytes.** *J Neuroimmunol.* 2010 ;218(1-2):57-66.
- Mizisin AP, Weerasuriya A. **Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult.** *Acta Neuropathol.* 2011;121(3):291-312.
- Nicol GD, Vasko MR. **Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks?** *Mol Interv.* 2007;7(1):26-41.
- Palomba R, Adiletta S, Candiello A, Pennimpede M, Bonaccia P, De Martino CJ. **Multimodal analgesia for chronic pain: rationale and future directions.** Naples Pain Conference (NPC): Research and Therapy for human and animal suffering MAY 16 - 19, 2010
- Parabita M, D'Amore RM, Marinocchi F, Matera MG, Izzo A, Russo GA. **Reduction of post stroke spasticity with Palmitoylethanolamide treatment.** XIV Congress of the European Shock Society. 2011. Taormina, August 31, September 2, 2011;121(3):291-312.
- Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S. **Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma.** *J Neuroinflammation.* 2013 Feb 1;10:20.
- Ren K, Dubner R. **Interactions between the immune and nervous systems in pain.** *Nat Med.* 2010;16(11):1267-76.
- Rosa AC, Fantozzi R. **Histamine in the neurogenic inflammation.** *Br J Pharmacol.* 2013;
- Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. **Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo.** *Brain Res.* 1999;4;849(1-2):1-15.
- Schiffilliti C., Cucinotta L., Fedele V., Ingegnesi C., Luca S., Leotta C. **Palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients.** *Panminerva Med.* (submitted) 2013
- Skaper SD, Facci L. **Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.** *Philos Trans R Soc Lond B Biol Sci.* 2012 Dec 5;367(1607):3312-25. Review.
- Skaper SD, Giusti P, Facci L. **Microglia and mast cells: two tracks on the road to neuroinflammation.** *FASEB J.* 2012 Aug;26(8):3103-17. Review.
- Szpak GM, Lewandowska E, Lechowicz W, Wierzbobrowicz T, Kulczycki J, Bertrand E, Pasennik E, Dymecki J. **The brain immune response in human prion diseases. Microglial activation and microglial disease. I. Sporadic Creutzfeldt-Jakob disease.** *Folia Neuropathol.* 2006;44(3):202-13.
- Truini A, Biasiotta A, Di Stefano G, Cesa SL, Leone C, Cartoni C, Federico V, Petrucci MT, Crucco G. **Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy.** *CNS Neurol Disord Drug Targets.* 2011;10(8):916-20.
- Wise LE, Cannavacciuolo R, Cravatt BF, Martin BF, Lichtman AH. **Evaluation of fatty acid amides in the carrageenan-induced paw edema model.** *Neuropharmacology.* 2008;54(1):181-8.
- Yuan H, Zhu X, Zhou S, Chen Q, Zhu X, Ma X, He X, Tian M, Shi X. **Role of mast cell activation in inducing microglial cells to release neurotrophin.** *J Neurosci Res.* 2010;88(6):1348-54.
- Zhang F, Vadakkan KI, Kim SS, Wu LJ, Shang Y, Zhuo M. **Selective activation of microglia in spinal cord but not higher cortical regions following nerve injury in adult mouse.** *Mol Pain.* 2008;18:4:15.
- Zheng FY, Xiao WH, Bennett GJ. **The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuries.** *Neuroscience.* 2011;176:447-54.